Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 03, 2023 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, GM of U.S. | June 05, 2023 | June 07, 2023 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Chief Commercial Officer | April 03, 2020 | April 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
Jazz Pharmaceuticals plc
Report date June 05, 2023 · Filed June 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,478 |
Reported balance
After 2023-06-05 transaction · row 1
1 source rowRow 1 · 2023-06-05 · Disposition to issuer · Disposed 2,082 · Balance 28,478 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Myovant Sciences Ltd.
Report date April 03, 2020 · Filed April 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 146,710 |
Reported balance
After 2020-04-03 transaction · row 1
1 source rowRow 1 · 2020-04-03 · Grant · Acquired 87,805 · Balance 146,710 F1: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2030-04-02 | Direct | 134,464 |
Reported balance
After 2020-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-03 · Grant · Acquired 134,464 · Balance 134,464 F2: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
F2: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2023 Filed Jun 7, 2023 23:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 2,082 | $129.73 | $270,097.86 |
DisclosureSEC source: 0001765581-23-000046 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP, GM of U.S. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,478 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 23:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,261 | $140.19 | $176,779.59 |
DisclosureSEC source: 0001765581-23-000036 · edgardoc.xml · nonDerivative · entry 2 Sablich Kim · CIK 0001758790 · EVP, GM of U.S., Commercial Ma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,560 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 23:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,752 | $139.42 | $244,263.84 |
DisclosureSEC source: 0001765581-23-000036 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP, GM of U.S., Commercial Ma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,821 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 05, 2023 Filed Mar 8, 2023 01:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,610 | $142.78 | $229,875.80 |
DisclosureSEC source: 0001765581-23-000017 · edgardoc.xml · nonDerivative · entry 2 Sablich Kim · CIK 0001758790 · EVP, GM of U.S., Commercial Ma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,573 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000017 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP, GM of U.S., Commercial Ma 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,183 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:50 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010160 · form4.xml · derivative · entry 1 Sablich Kim · CIK 0001758790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 101 | $152.60 | $15,412.10 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 7 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,754 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.595 to $152.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,317 | $151.87 | $200,016.08 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 6 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,855 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $151.35 to $152.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 573 | $150.68 | $86,337.35 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 5 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,172 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.32 to $151.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 250 | $149.22 | $37,306.23 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 4 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,745 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.12 to $149.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $148.21 | $29,641.80 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 3 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,995 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.05 to $148.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,388 | $152.15 | $211,184.20 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 2 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,195 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,759 | $149.25 | $262,530.75 |
DisclosureSEC source: 0001765581-22-000057 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,583 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001140361-22-009263 · form4.xml · derivative · entry 2 Sablich Kim · CIK 0001758790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-009263 · form4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 23:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 746 | $153.96 | $114,854.16 |
DisclosureSEC source: 0001765581-22-000028 · edgardoc.xml · nonDerivative · entry 2 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,342 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 23:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 9,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000028 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,088 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 00:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,748 | $135.01 | $371,000.34 |
DisclosureSEC source: 0001765581-21-000125 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,135 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.075, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 05, 2021 Filed Jun 9, 2021 22:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,452 | $176.47 | $256,234.44 |
DisclosureSEC source: 0001765581-21-000061 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,883 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 17:35 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001209191-21-028175 · doc4.xml · derivative · entry 1 Sablich Kim · CIK 0001758790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-22 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from April 23, 2019 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000028 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,335 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 38,856 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000065 · edgardoc.xml · derivative · entry 3 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,856 Underlying: Ordinary Shares · 38,856 shares Expires 2030-08-05 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of June 1, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 3,144 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000065 · edgardoc.xml · derivative · entry 2 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2030-08-05 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of June 1, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000065 · edgardoc.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · EVP & GM, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:14 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 134,464 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001209191-20-023796 · doc4.xml · derivative · entry 2 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,464 Underlying: Common Shares · 134,464 shares Expires 2030-04-02 F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:14 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 87,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023796 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,710 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 16:32 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 15 | $6.93 | $103.95 |
DisclosureSEC source: 0001209191-20-020279 · doc4.xml · nonDerivative · entry 2 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,905 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 16:32 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 770 | $7.38 | $5,682.60 |
DisclosureSEC source: 0001209191-20-020279 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,920 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 17:28 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 4,840 | $14.04 | $67,953.60 |
DisclosureSEC source: 0001209191-20-003741 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,690 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $14.00 to $14.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 16:25 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 2,585 | $16.22 | $41,928.70 |
DisclosureSEC source: 0001209191-19-061300 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,530 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:59 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047548 · doc4.xml · derivative · entry 5 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,130 Underlying: Common Shares · 66,130 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:59 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-047548 · doc4.xml · derivative · entry 4 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 66,130 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:59 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 133,500 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047548 · doc4.xml · derivative · entry 3 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,500 Underlying: Common Shares · 133,500 shares Expires 2028-12-16 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on December 17, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:59 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 133,500 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0001209191-19-047548 · doc4.xml · derivative · entry 2 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 133,500 shares Expires 2028-12-16 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on December 17, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:59 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 37,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047548 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,115 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 18:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-024148 · doc4.xml · derivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,130 Underlying: Common Stock · 66,130 shares Expires 2029-05-04 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 17:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 133,500 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0001209191-18-063255 · doc4.xml · derivative · entry 2 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,500 Underlying: Common Shares · 133,500 shares Expires 2028-12-16 F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on December 17, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 17:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 29,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063255 · doc4.xml · nonDerivative · entry 1 Sablich Kim · CIK 0001758790 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 F1 · security: Represents common shares underlying a restricted stock unit award. F2 · shares: 1/4 of the common shares underlying this restricted stock unit award vest on December 17, 2019, and 1/16 of the common shares underlying this restricted stock unit award vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.